Cytochemical Characterization of Cerebrospinal Fluid Macrophage Inclusions in Pediatric Patients Receiving Intrathecal Nusinersen (SPINRAZA®) for Spinal Muscular Atrophy

被引:5
作者
Schafernak, Kristian T. [1 ]
Jacobsen, Jeffrey R. [1 ]
Hernandez, Dulce [1 ]
Kaye, Robin D. [2 ]
Perez, Sylvia E. [3 ]
机构
[1] Phoenix Childrens Hosp, Dept Pathol & Lab Med, Phoenix, AZ 85016 USA
[2] Phoenix Childrens Hosp, Dept Radiol, Phoenix, AZ USA
[3] Barrow Neurol Inst, Dept Neurobiol, Phoenix, AZ 85013 USA
关键词
Nusinersen; Spinal muscular atrophy; Cerebrospinal fluid; Cytology; Macrophage; DIAGNOSIS;
D O I
10.1159/000518005
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Introduction: Spinal muscular atrophy (SMA) is a debilitating neuromuscular disorder caused by biallelic deletion of the SMN1 gene. Nusinersen, an antisense oligonucleotide delivered intrathecally, binds to the pre-mRNA of SMN1's pseudogene, SMN2, to prevent exon skipping and produce functional SMN protein to compensate for the deficiency caused by SMN1 deletion. Case Presentation: We reviewed 15 cerebrospinal fluid (CSF) cytology specimens from 8 patients receiving nusinersen for SMA. Macrophages with peculiar inclusions ("nusinophages") were seen in 8 specimens from 4 of the patients: 1 infant and 3 children with SMA type 1. This finding has only previously been reported in adults with SMA types 2 and 3 and in 2 infants with SMA type 1. Discussion/Conclusion: Specimens containing nusinophages had a significantly higher proportion of macrophages and lower proportion of lymphocytes than those in which nusinophages were not detected. The macrophage inclusions do not represent iron or microorganisms and instead are composed, at least in part, of glycosaminoglycans. Because CSF is a common specimen type, cytotechnologists and cytopathologists need to be aware of these inclusions, so they do not interpret them erroneously as evidence of infection or hemorrhage, especially in light of the fact that oligonucleotide therapy has been approved for a variety of conditions and is currently under investigation for intrathecal delivery in several other neurodegenerative disorders.
引用
收藏
页码:79 / 84
页数:6
相关论文
共 17 条
[1]   SPINAL MUSCULAR ATROPHY: DIAGNOSIS AND MANAGEMENT IN A NEW THERAPEUTIC ERA [J].
Arnold, W. David ;
Kassar, Darine ;
Kissel, John T. .
MUSCLE & NERVE, 2015, 51 (02) :157-167
[2]  
Australian Government Department of Health Therapeutic Goods Administration, AUSTR PUBL ASS REP N
[3]  
Bancroft J. D., 2008, THEORY PRACTICE HIST
[4]   The light at the end of the tunnel gets vivid for spinal muscular atrophy An Editorial Highlight for "Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy" on [J].
Dutta, Debashis ;
Chandra, Goutam ;
Mohanakumar, Kochupurackal P. .
JOURNAL OF NEUROCHEMISTRY, 2020, 153 (05) :545-548
[5]  
European Medicines Agency Committee for Medicinal Products for Human Use [Internet, ASS REP SPINR
[6]   Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study [J].
Finkel, Richard S. ;
Chiriboga, Claudia A. ;
Vajsar, Jiri ;
Day, John W. ;
Montes, Jacqueline ;
De Vivo, Darryl C. ;
Yamashita, Mason ;
Rigo, Frank ;
Hung, Gene ;
Schneider, Eugene ;
Norris, Daniel A. ;
Xia, Shuting ;
Bennett, C. Frank ;
Bishop, Kathie M. .
LANCET, 2016, 388 (10063) :3017-3026
[7]  
Food and Drug Administration Center for Drug Evaluation and Research, PHARM TOX REV EV NUS
[8]   Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps [J].
Gidaro, Teresa ;
Servais, Laurent .
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2019, 61 (01) :19-+
[9]   Routine Cerebrospinal Fluid Cytology Reveals Unique Inclusions in Macrophages During Treatment With Nusinersen [J].
Gingele, Stefan ;
Huemmert, Martin W. ;
Alvermann, Sascha ;
Jendretzky, Konstantin F. ;
Boenig, Lena ;
Brieskom, Marina ;
Schwenkenbecher, Philipp ;
Suehs, Kurt-Wolfram ;
Mueschen, Lars H. ;
Osmanovic, Alma ;
Schreiber-Katz, Olivia ;
Stangel, Martin ;
Petri, Susanne ;
Skripuletz, Thomas .
FRONTIERS IN NEUROLOGY, 2019, 10
[10]   Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy [J].
Kessler, Tobias ;
Latzer, Pauline ;
Schmid, Dominic ;
Warnken, Uwe ;
Saffari, Afshin ;
Ziegler, Andreas ;
Kollmer, Jennifer ;
Moehlenbruch, Markus ;
Ulfert, Christian ;
Herweh, Christian ;
Wildemann, Brigitte ;
Wick, Wolfgang ;
Weiler, Markus .
JOURNAL OF NEUROCHEMISTRY, 2020, 153 (05) :650-661